RA Capital Management STRO Position
Exited3-Fund ConvergenceRA Capital Management exited their position in SUTRO BIOPHARMA, INC. (STRO) in Q2 2025, after holding the stock for 2 quarters.
The position was first reported in Q1 2025 and has been tracked across 2 quarterly 13F filings.
STRO is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About SUTRO BIOPHARMA, INC.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
3.3%
3.7 days to cover
RA Capital Management STRO Position History
Frequently Asked Questions
Does RA Capital Management own STRO?
No. RA Capital Management exited their position in SUTRO BIOPHARMA, INC. (STRO) in Q2 2025. They previously held the stock for 2 quarters.
How many hedge funds own STRO?
3 specialist biotech hedge funds currently hold STRO, including BVF Partners, Tang Capital Management, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy STRO?
RA Capital Management's position in STRO was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's STRO position increasing or decreasing?
RA Capital Management completely exited their STRO position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
STROCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →